NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

LeonaBio, Inc. (LONA) Stock Analysis

LeonaBio, Inc. (LONA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LONA

$7.56

−$0.14 (−1.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LONA with… →

LONA Key Statistics

As of Sep 4, 2026
Trading
Open
$7.93
Previous Close
$7.70
Day's Range
7.44–7.93
52-Week Range
3.53–14.21
Volume
14.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.05
Valuation
Market Cap
$71.23M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−23.01
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$105.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.42M
1-Year Return
+95.35%
Dividend and dates
Avg Volume
36.99K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LONA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−0.13%
2025+28.96%
2024−75.84%
2023−23.34%
2022−75.67%
2021−61.96%
2020 (partial year)+100.18%

As of September 4, 2026.

LONA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$105.61M—
2024$0.00−$96.94M—
2023$0.00−$117.67M—
2022$0.00−$95.64M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$34.18M−$105.61M—
2024$0.00—−$96.78M−$96.94M—
2023$0.00—−$126.94M−$117.67M—
2022$0.00—−$88.86M−$95.64M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LONA Valuation vs Biotechnology Median

Median of 656 stocks
MetricLONABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values LeonaBio, Inc. (LONA) at $71.23M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 19.

The 52-week range on file runs from $3.53 to $14.21. LONA last closed at $7.56 on September 4, 2026. That is −$0.14 (−1.82%) against the previous close. The latest close sits 114.16% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $105.61M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −23.01.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 2.05. Annualized volatility over the trailing 6 years is 92.95%. The trailing one-year price return is +95.35%. Measured over 5 years, that is −41.09% a year compounded.

Growth & Income

The record shows no dividend for LONA.

The strongest complete calendar year on file is 2025 at +28.96%; the weakest is 2024 at −75.84%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −0.13% year to date.

Peer Comparison

LeonaBio, Inc. (LONA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
LeonaBio, Inc. LONA $71.23M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. LeonaBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About LeonaBio, Inc.

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Visit website →